GroundRules
Tex. Health and Safety Code § 491.052 (3): PATIENT ELIGIBILITY.
Where this section sits in the code
- HEALTH AND SAFETY CODE
- TITLE 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES
- SUBTITLE C. SUBSTANCE ABUSE REGULATION AND CRIMES Chapter 491, consisting of Secs. 491.001 to 491.151, was added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984), Sec. 1. For another Chapter 491, consisting of Secs. 491.001 to 491.103, added by Acts 2025, 89th Leg., R.S., Ch. 333 (S.B. 2308), Sec. 1, see Sec. 491.001 et seq., post. For another Chapter 491, consisting of Secs. 491.001 to 491.151, added by Acts 2025, 89th Leg., R.S., Ch. 352 (S.B. 670), Sec. 2, see Sec. 491.001 et seq., post.
- CHAPTER 491. ACCESS TO INDIVIDUALIZED INVESTIGATIONAL TREATMENTS FOR PATIENTS WITH LIFE-THREATENING OR SEVERELY DEBILITATING ILLNESSES
- SUBCHAPTER B. ACCESS TO INDIVIDUALIZED INVESTIGATIONAL TREATMENT
A patient is eligible to access an individualized investigational treatment under this chapter if:
(1) the patient:
(A) has a life-threatening illness or severely debilitating illness;
(B) has considered all other treatment options currently approved by the United States Food and Drug Administration; and
(C) has given written informed consent for access to the treatment; and
(2) the patient's physician:
(A) attests to the patient's life-threatening illness or severely debilitating illness and the patient's eligibility under this section; and
(B) recommends the treatment for the patient based on analysis of the patient's genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products such as enzymes and other types of proteins, or metabolites.
Added by Acts 2025, 89th Leg., R.S., Ch. 285 (S.B. 984), Sec. 1, eff. September 1, 2025.
Collected 2026-08-27T01:47:17Z. Source file · JSON